Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹162 Cr
Revenue (TTM)
₹28 Cr
Net Profit (TTM)
₹3 Cr
ROE
4.3 %
ROCE
3.8 %
P/E Ratio
54.9
P/B Ratio
3.6
Industry P/E
33.74
EV/EBITDA
22.9
Div. Yield
0 %
Debt to Equity
1
Book Value
₹73.1
EPS
₹4.7
Face value
10
Shares outstanding
6,232,500
CFO
₹68.73 Cr
EBITDA
₹61.19 Cr
Net Profit
₹35.78 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Auro Laboratories
| 4.4 | -10.8 | 6.8 | 7.6 | 68.3 | 26.0 | 29.2 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Auro Laboratories
| -5.2 | 97.6 | 64.2 | -26.9 | 30.0 | 76.3 | -15.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Auro Laboratories
|
260.4 | 162.3 | 28.4 | 3.0 | 17.9 | 6.8 | 54.9 | 3.6 |
| 352.7 | 3,213.2 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.9 | 2.1 | |
| 989.6 | 12,119.0 | 2,512.3 | 543.7 | 28.3 | 19.3 | 22.3 | 3.8 | |
| 357.4 | 6,190.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.1 | 4.8 | |
| 1,025.1 | 10,733.1 | 1,158.7 | 309.6 | 31.9 | 17.3 | 34.3 | 5.7 | |
| 1,547.6 | 29,354.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.7 | 5.9 | |
| 12,433.0 | 15,953.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 89.1 | 9.6 | |
| 1,921.2 | 3,180.4 | 673.7 | 202.6 | 17.6 | 19.4 | 15.7 | 5.5 | |
| 784.3 | 3,617.1 | 588.5 | 102.9 | 22.1 | 12.7 | 35.6 | 4.3 | |
| 158.0 | 4,151.0 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 6.2 |
No Review & Analysis are available.
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency,... anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India. Read more
Incorporated
1989
Chairman
Sharat Deorah
Managing Director
Sharat Deorah
Headquarters
Thane, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Auro Laboratories Ltd is ₹260.35 (BSE) as of 02-Apr-2026 IST. Auro Laboratories Ltd has given a return of 68.27% in the last 3 years.
The P/E ratio of Auro Laboratories Ltd is 54.89 times as on 02-Apr-2026, a 63 premium to its peers’ median range of 33.74 times.
The P/B ratio of Auro Laboratories Ltd is 3.56 times as on 02-Apr-2026, a 67 premium to its peers’ median range of 2.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
78.15
|
3.34
|
|
2024
|
12.89
|
2.39
|
|
2023
|
13.95
|
1.00
|
|
2022
|
21.98
|
1.98
|
|
2021
|
7.04
|
1.77
|
The 52-week high and low of Auro Laboratories Ltd are Rs 317.00 and Rs 159.00 as of 04-Apr-2026.
Auro Laboratories Ltd has a market capitalisation of ₹ 162 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Auro Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-11.55
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.